Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029009 · ClinicalTrials.gov registry record · Phase 2
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
A Phase 2 study of Maturity Onset Diabetes of the Young, sponsored by Man.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07029009: Recruiting Phase 2 study of Maturity Onset Diabetes of the Young, sponsored by Man.
NCT07029009 is a Phase 2 study of Maturity Onset Diabetes of the Young that is actively recruiting participants, run by Man. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029009, a Phase 2 study of Maturity Onset Diabetes of the Young, is actively recruiting participants, sponsored by Man.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.
Primary Outcome
Hemoglobin A1c
Conditions Studied
Interventions
- DRUG Liraglutide
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT07029009 shows while recruiting
NCT07029009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Maturity Onset Diabetes of the Young appearing as the primary indexed condition, and to 1 intervention - of which Liraglutide is the first listed.
NCT07029009 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07029009 about?
NCT07029009 is a clinical study titled "Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)". The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects t...
What is the current status of trial NCT07029009?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-08. Estimated completion is 2027-01.
What conditions does trial NCT07029009 study?
This clinical trial studies the following conditions: Maturity Onset Diabetes of the Young.
What interventions are being tested in trial NCT07029009?
The interventions under investigation include: Liraglutide (DRUG).
Who is sponsoring clinical trial NCT07029009?
This trial is sponsored by Man, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029009 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07029009's enrollment target sits among peer trials
50 1195th of 2000 higher than 741 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI